Differences in the prevalence of metabolic syndrome according to the ATP-III and WHO definitions;Diferencias en la prevalencia del síndrome metabólico según las definiciones del ATP-III y la OMS

Medicina Clinica

Volumn 124, Issue 10, 2005, Pages 368-370

  Alvarez Cosmea, Artemio ^a   López Fernández, Vicente ^a   Suárez García, Saúl ^a   Arias García, Teresa ^a   Prieto Díaz, Miguel Ángel ^b   Díaz González, Luis ^a  

^a Centro de Salud Ventanielles Colloto   (Spain)

^b Centro de Salud Vallobin   (Spain)

Author keywords

Diagnosis; Metabolic syndrome; Prevalence; Primary care

Indexed keywords

ADULT; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NOMENCLATURE; POPULATION RESEARCH; PREVALENCE; PRIMARY MEDICAL CARE; RISK FACTOR; SENSITIVITY AND SPECIFICITY; WORLD HEALTH ORGANIZATION;

EID: 17144391140     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13072570     Document Type: Article

References (10)

1. Banegas JR, Ruilope LM. Epidemia de enfermedades metabolicas. Una llamada de atención. Med Clin (Barc). 2003;120:99-100.
2. National Institutes of Health. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Full Report. Bethesda: National Institutes of Health. National Heart, Lung, and Blood Institute, 2002.
3. Definition, diagnosis and classification of diabetes mellitus and its complications: Report of a WHO Consultation. Geneva: Department of Noncommunicable Disease Surveillance, World Health Organization, 1999.
4. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA. 2002;287:356-9.
5. Grupo de Trabajo Resistencia a la insulina de la Sociedad Española de Diabetes. Resistencia a la insulina y su implicación en múltiples factores de riesgo asociados a diabetes tipo 2. Med Clin (Barc). 2002;119:458-63.
6. Ascaso JF, Romero P, Real JT, Priego A, Valdecabres C, Carmena R. Cuantificación de la insulinorresistencia con los valores de insulina basal e indice HOMA en una población no diabética. Med Clin (Barc). 2001; 117:530-3.
7. Silva LC. Excursión a la regresión logística en ciencias de la salud. Madrid: Ediciones Diaz Santos; 1994. p. 97-119.
8. Alvarez León EE, Rivas Barba L, Serra Majem L. Prevalencia del síndrome metabólico en la población de la Comunidad Canaria. Med Clin (Barc). 2003;120:172-4.
9. Ford ES, Giles WH. A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care. 2003;26: 575-81.
10. Aguilar-Salinas CA, Rojas R, Gómez-Pérez FJ, Valles V, Ríos-Torres JM, Franco A, et al. Analysis of the agreement between the World Health Organization criteria and the National Cholesterol Education Program-III definition of the metabolic syndrome. Diabetes Care. 2003;26:1635.